Arthur Volovetskiy

Mr. Arthur Volovetskiy


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Biophysics
Verified
Journal Article
Closed access
PDF file
AVArthur Volovetskiy
Arthur Volovetskiy
Natalia ShilyaginaNatalia Shilyagina
Natalia Shilyagina
VDV. V. Dudenkova
V. V. Dudenkova
SPS. O. Pasynkova
S. O. Pasynkova
AIA. A. Ignatova
A. A. Ignatova
AMA. V. Maslennikova
A. V. Maslennikova
Boron neutron-capture therapy of cancer is based on the ability of the 10B isotope to capture thermal neutrons; it is one of the most promising techniques in radiation therapy. The high content and...

Verified
Journal Article
Open access
PDF file
AVArthur Volovetskiy
Arthur Volovetskiy
VSVladimir Sukhov
Vladimir Sukhov
Irina V. BalalaevaIrina V. Balalaeva
Irina V. Balalaeva
Varvara Vadimovna DudenkovaVarvara Vadimovna Dudenkova
Varvara Vadimovna Dudenkova
Natalia ShilyaginaNatalia Shilyagina
Natalia Shilyagina
AMAnna Valer'evna Maslennikova
Anna Valer'evna Maslennikova
The necessary precondition for efficient boron neutron capture therapy (BNCT) is control over the content of isotope 10B in the tumor and normal tissues. In the case of boron-containing porphyrins, the fluorescent part of molecule can be used for quantitative assessment of the boron content. Study Objective: We performed a study of the biodistribution of the chlorin e6-Cobalt bis(dicarbollide) conjugate in carcinoma-bearing Balb/c mice using ex vivo fluorescence imaging, and developed a mathematical model describing boron accumulation and release based on the obtained experimental data. Materials and Methods: The study was performed on Balb/c tumor-bearing mice (CT-26 tumor model). A solution of the chlorin e6-Cobalt bis(dicarbollide) conjugate (CCDC) was injected into the blood at a dose of 10 mg/kg of the animal’s weight. Analysis of the fluorescence signal intensity was performed at several time points by spectrofluorimetry in blood and by laser scanning microscopy in muscle, liver, and tumor tissues. The boron content in the same samples was determined by mass spectroscopy with inductively coupled plasma. Results: Analysis of a linear approximation between the fluorescence intensity and boron content in the tissues demonstrated a satisfactory value of approximation reliability with a Spearman’s rank correlation coefficient of r = 0.938, p < 0.01. The dynamics of the boron concentration change in various organs, calculated on the basis of the fluorescence intensity, enabled the development of a model describing the accumulation of the studied compound and its distribution in tissues. The obtained results reveal a high level of correspondence between the model and experimental data.

1 December 2020 in Sovremennye tehnologii v medicine
Verified
Journal Article
Open access
AVArthur Volovetskiy
Arthur Volovetskiy
PMP.A. Malinina
P.A. Malinina
AKA.Y. Kapitannikova
A.Y. Kapitannikova
SSS.V. Smetanina
S.V. Smetanina
IKI.A. Kruglova
I.A. Kruglova
AMA.V. Maslennikova
A.V. Maslennikova
The aim of the investigation was to study the potential of an innovative microfluidic technology for the isolation of circulating tumor cells (CTCs) from the peripheral blood samples of cancer patients. Materials and Methods. Peripheral blood samples from 5 patients with disseminated malignant tumors of epithelial origin were processed with the use of the microfluidic technology (based on a specifically designed silicone chip). The cells were separated according to their density criterion based on the lateral migration of solid particles in a liquid due to inertial forces. With the help of the designed chip configuration, the cells over 13 mu m in size which is larger than the standard size of blood cells were isolated. The resulting target cell fraction was stained by the Romanowsky-Giemsa method. Staining with the fluorescent Anti-Cytokeratin (CK3-6H5)-FITC antibody was carried out to confirm the epithelial nature of the cells, and the DAPI dye was used to contrast the nucleus. The blood of a healthy volunteer and tumor cells of the A549 line were used for the immunocytochemical studies. Results. The tumor cells in peripheral blood (in the number of 1 to 9) were detected in all 5 patients. CTC clusters of 2-5 cells were identified in blood samples from the patients with laryngeal cancer, non-small cell lung cancer, and floor of the mouth cancer. A bright saturated staining of the A549 tumor cells was obtained using the Anti-Cytokeratin (CK3-6H5)-FITC antibody, corresponding to the staining of the cytoskeleton of epithelial cells. Successful nuclear staining with DAPI confirmed that the isolated target cells are not damaged during microfluidic separation. Conclusion. The microfluidic technology that has been used enables effective intact CTCs isolating from the peripheral blood of cancer patients. The epithelial nature of the isolated cells can be confirmed by immunocytochemical studies.

15 April 2025 in Micromachines
Verified
Journal Article
Open access
PDF file
AVArthur Volovetskiy
Arthur Volovetskiy
VNVictoria A. Novikova
Victoria A. Novikova
ABAnastasia Boloban
Anastasia Boloban
ARAlexey Rzhevskiy
Alexey Rzhevskiy
AKAlina Yu. Kapitannikova
Alina Yu. Kapitannikova
AMAnna Valer'evna Maslennikova
Anna Valer'evna Maslennikova
Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, n = 10, vs. median survival 8 months, n = 19, respectively with HR = 2.6, 95% CI 1.07 to 6.4).